Treatment Completion and Implementation by Patients Initiating Ticagrelor

Main Article Content

Jean-Pierre Grégoire
Paul Poirier
Norma Perez
Éric Demers
Jocelyne Moisan


drug utilization, adherence, ticagrelor, acute coronary syndrome


In secondary prevention of adverse events and death following acute coronary syndrome, patients may benefit from adhering to a ticagrelor treatment.
The authors assessed the proportion of new ticagrelor users who completed 12 months of treatment, ex-plored the factors associated with treatment completion and, among the completers, evaluated the 12-month treatment implementation.
A retrospective administrative health database inception cohort study was conducted in a population that included Quebec residents ≥18 years of age who initiated ticagrelor between January 1, 2012 and March 31, 2014. A patient still on ticagrelor at the end of the 12-month period after treatment initiation was considered to have completed the treatment. Factors associated with treatment completion were identified using log-binomial regression. Implementation was assessed using the proportion of days covered (PDC).

Of the 3,600 patients, 2,235 (62.1%) completed 12 months of treatment. The patients who were more likely to complete their treatment included those who had visited a general practitioner, had a percutane-ous coronary intervention, used a statin or fibrate, and those who used an antihypertensive drug during the year preceding the ticagrelor treatment initiation. Older patients, those with atrial fibrillation, those who had ≥ 6 physician visits and those who used an anticoagulant were less likely to complete the 12-month treatment. The median PDC was 96.2%.
Treatment completion might be improved. Among patients who completed the treatment, implementation was high. The factors associated with completion could help to identify patients who might benefit from interventions that aim to optimize treatment completion.

Abstract 33 | pdf Downloads 38


1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.
3. Wahl C, Gregoire JP, Teo K, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q 2005;8:65–70.
4. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73:691–705.
5. Tanguay JF, Bell AD, Ackman ML, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29:1334–45.
6. Dehghani P, Chopra V, Bell A, et al. Southern Sas-katchewan ticagrelor registry experience. Patient Pref Adherence 2014;8:1427–35.
7. Simeone JC, Molife C, Marrett E, et al. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs 2015;15:337–50.
8. Régie de l’assurance maladie du Québec. Rapport an-nuel de gestion 2016-2017. Bibliothèque et Archivesnationales du Québec. SiteCollectionDocuments/citoyens/fr/rapports/rap-pann1617.pdf. Published 2017. Accessed February 17, 2019.
9. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemio-logical research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999–1009.
10. Grégoire J-P, Moisan J. Assessment of adherence to drug treatment in database research. In: Elseviers M, Wettermark B, Almarsdóttir A, et al., eds. Drug Utili-zation Research: Methods and Applications. Toronto: Wiley-Blackwell; 2016:369–80.
11. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: fre-quency, predictors and associations with death and myocardial infarction–a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011;32:2376–86.
12. Bergmeijer TO, Janssen PWA, van Oevelen M, et al. Incidence and causes for early ticagrelor discontinuation: A “real-world” Dutch registry experience. Cardiology 2017;138:164–68.
13. Sra S, Tan MK, Mehta SR, et al. Ischemic and bleed-ing events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Ca-nadian observational AntiPlatelet sTudy. Am Heart J 2016;180:82–89.
14. Mathews R, Wang TY, Honeycutt E, et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. Am Heart J 2015;170:62–69.
15. Prami T, Khanfir H, Deleskog A, et al. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. BMJ Open 2016;6:e012604.
16. Claeys MJ, Beauloye C, Pourbaix S, Sinnaeve PR, Rewinder Study G. Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study. Eur Heart J Cardiovasc Pharmacother 2017;3:189–97.